Catalent, Inc.

NYSE:CTLT Stock Report

Market Cap: US$11.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Catalent Future Growth

Future criteria checks 3/6

Catalent is forecast to grow earnings and revenue by 74.5% and 6.8% per annum respectively while EPS is expected to grow by 76.9% per annum.

Key information

74.5%

Earnings growth rate

76.89%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate6.8%
Future return on equityn/a
Analyst coverage

Good

Last updated06 Dec 2024

Recent future growth updates

Recent updates

Seeking Alpha • Jun 25

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Summary Catalent's stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candidates in their pipeline. Thus, Elevidys's monopoly could be under a threat. Based on my technology assessment, only two product candidates have the potential to disrupt Elevidys monopoly in the next two to three years. Thus, I consider that CTLT’s and SRPT’s revenue driven by Elevidys is not only safe, but poised to grow given the label expansion in the U.S. Read the full article on Seeking Alpha
Seeking Alpha • Feb 07

Catalent - Novo Holdings Merger: Attractive Spread

Summary We anticipate an FTC review for the Novo Holdings acquisition of Catalent, Inc. but see no grounds for blocking. Timetable risk due to regulatory approval under HSR Act. Attractive 10.2% gross spread with favourable probability of closing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

Catalent: Debt Remains An Overhang

Summary Today, we revisit drug manufacturer Catalent, Inc., which has expanded its board membership at the behest of activist investor Elliott Management. Analysts remain skeptical about Catalent's turnaround story, but the company has made progress and has brought in new directors and executives. An updated analysis of Catalent, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Catalent Remains Overvalued

Summary Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended June 2023, but Biologics revenue was down 37% year-over-year. Catalent's margins have weakened, with gross profit down 49% year-over-year and EBITDA down over 90% year-over-year. Catalent trades at nearly 18x forward EBITDA. Catalent is overvalued, time to sell the stock. Read the full article on Seeking Alpha
Seeking Alpha • Jul 31

Catalent: Myriad Issues To Fix

Summary Today, we take a look at Catalent, a drug manufacturer that has been beset by myriad issues over the past year resulting in a 55% drop in the stock. The company has recently drawn the interest of activist investor Elliott Management, meaning significant changes could be ahead. Will this halt the decline in the shares? An investment analysis on Catalent follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Why did Catalent stock soar today? Potential takeover by Danaher

Catalent closed Monday up ~20% on Monday following a report over the weekend that Danaher (NYSE:DHR) was interested in acquiring the contract manufacturer. BofA Securities analyst Michael Ryskin said that the premium Danaher (DHR) would have to pay for such a deal is "up for debate." He has Danaher (DHR) as a buy. Meanwhile, Jefferies' David Windley, who rates both companies a buy, said a deal could value Catalent (NYSE:CTLT) at ~$93/share. Seeking Alpha's Quant Rating views Catalent (CTLT) and Danaher (DHR) as a hold.

Earnings and Revenue Growth Forecasts

NYSE:CTLT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20275,32479705992
6/30/20264,978401005577
6/30/20254,625-188-2242146
9/30/20244,422-41399399N/A
6/30/20244,381-1,043-59268N/A
3/31/20244,135-1,176-123250N/A
12/31/20234,098-1,302-263174N/A
9/30/20234,223-1,015-235276N/A
6/30/20234,263-256-322254N/A
3/31/20234,49521-563127N/A
12/31/20224,731389-371329N/A
9/30/20224,799399-471184N/A
6/30/20224,802483-221439N/A
3/31/20224,703485-110504N/A
12/31/20214,483561-183441N/A
9/30/20214,177544-244446N/A
6/30/20213,998529-253433N/A
3/31/20213,757494-188471N/A
12/31/20203,465289-135518N/A
9/30/20203,27525022565N/A
6/30/20203,094173-26440N/A
3/31/20202,872104-37356N/A
12/31/20192,72912420309N/A
9/30/20192,631138-22232N/A
6/30/20192,51813230248N/A
3/31/20192,47814975263N/A
12/31/20182,488136108283N/A
9/30/20182,47165160332N/A
6/30/20182,46384N/A375N/A
3/31/20182,39563N/A371N/A
12/31/20172,30070N/A380N/A
9/30/20172,177109N/A335N/A
6/30/20172,075110N/A300N/A
3/31/20171,991106N/A233N/A
12/31/20161,89691N/A180N/A
9/30/20161,867104N/A159N/A
6/30/20161,848112N/A155N/A
3/31/20161,826207N/A199N/A
12/31/20151,835228N/A243N/A
9/30/20151,836244N/A257N/A
6/30/20151,831212N/A172N/A
3/31/20151,84086N/A180N/A
12/31/20141,84762N/A138N/A
9/30/20141,832-3N/A113N/A
6/30/20141,82819N/A178N/A
3/31/20141,8132N/A148N/A
12/31/20131,807-20N/A152N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTLT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CTLT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CTLT is expected to become profitable in the next 3 years.

Revenue vs Market: CTLT's revenue (6.8% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: CTLT's revenue (6.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CTLT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 12:38
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Catalent, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanGoldman Sachs
Tycho PetersonJ.P. Morgan
Rachel Vatnsdal OlsonJ.P. Morgan